Risk‐adapted treatment in multiple myeloma: Does more make it merrier?

• Published in: British journal of haematology Vol. 205; no. 3; pp. 767 - 769
• Main Authors: Zanwar, Saurabh, Galarza Fortuna, Gliceida M., Sborov, Douglas W.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2024
• Subjects: Bispecific antibodies; Chimeric antigen receptors; Clinical trials; Cytogenetics; Fluorescence in situ hybridization; high‐risk multiple myeloma; HRMM; Humans; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - therapy; phase 3; Risk Assessment; phase 3; high‐risk multiple myeloma; HRMM
• ISSN: 0007-1048; 1365-2141; 1365-2141
• DOI: 10.1111/bjh.19676

Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T‐cell redirecting bispecific antibodies and chimeric antigen receptor T‐cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833‐839.